• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by BeOne Medicines Ltd.

    6/6/25 4:16:22 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONC alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001042047
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    BeOne Medicines Ltd.
    SEC File Number
    001-37686
    Address of Issuer
    94 Solaris Avenue, Camana Bay
    Grand Cayman
    CAYMAN ISLANDS
    KY1 1108
    Phone
    345-949-4123
    Name of Person for Whose Account the Securities are To Be Sold
    JOHN OYLER
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    ADS
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    51271295946.1510955839406/06/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    ADS06/05/2025Restricted stock vesting under a registered planIssuerCheckbox not checked512706/05/2025Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    JOHN OYLER
    94 Solaris Avenue, Camana Bay
    Grand Cayman � E9 � KY1 1108
    ADS03/10/20254121010000480.15
    JOHN OYLER
    94 Solaris Avenue, Camana Bay
    Grand Cayman � E9 � KY1 1108
    ADS03/07/20255859014596245.47

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/06/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ John Oyler

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ONC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONC

    DatePrice TargetRatingAnalyst
    4/7/2025$312.00Outperform
    RBC Capital Mkts
    3/3/2025$207.00 → $320.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ONC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

      Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitor Data underscore strength of emerging breast cancer pipeline as part of BeOne's global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanc

      6/2/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

      BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational status At 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation st

      5/31/25 8:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

      BeOne well-positioned to deliver transformative treatments to patients worldwide with powerful oncology portfolio, pioneering clinical development approach, and expanded global manufacturing and commercial capabilities Redomiciliation to Switzerland bolsters Company's presence in leading global biopharmaceutical hub, marks next step in becoming a diversified biotechnology company focused on oncology BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation to Switzerland are officially in effect, marking a significant milestone in the Company's evolution. This press releas

      5/27/25 8:30:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yi Qingqing was granted 10,985 units of Ordinary Shares, increasing direct ownership by 24% to 56,940 units (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      5/23/25 4:05:13 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sharp Shalini was granted 10,985 units of Ordinary Shares, increasing direct ownership by 135% to 19,136 units (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      5/22/25 7:47:00 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brandicourt Olivier was granted 10,985 units of Ordinary Shares, increasing direct ownership by 67% to 27,326 units (SEC Form 4)

      4 - BeiGene, Ltd. (0001651308) (Issuer)

      5/22/25 7:46:02 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Financials

    Live finance-specific insights

    See more
    • BeiGene Announces First Quarter 2025 Financial Results and Business Updates

      First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

      5/7/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene to Announce First Quarter 2025 Financial Results on May 7

      BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company's website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the schedul

      4/17/25 6:01:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Total global revenues of $1.1 billion and $3.8 billion for the fourth quarter and full year, increases of 78% and 55%, respectively; narrowed GAAP operating loss and achieved full-year positive non-GAAP operating income Global BRUKINSA revenues of $828 million and $2.6 billion for the fourth quarter and full year, increases of 100% and 105%, respectively; progressed pivotal-stage programs for BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673 Advanced six and 13 New Molecular Entities (NMEs) into the clinic in the fourth quarter and full year, respectively; anticipate multiple data readouts for innovative solid tumor programs in 1H 2025 Full year 2025 revenue guidance of $4.9 billi

      2/27/25 6:00:00 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on BeiGene with a new price target

      RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00

      4/7/25 8:43:36 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene upgraded by BofA Securities with a new price target

      BofA Securities upgraded BeiGene from Neutral to Buy and set a new price target of $320.00 from $207.00 previously

      3/3/25 7:35:01 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONC
    SEC Filings

    See more
    • SEC Form 144 filed by BeOne Medicines Ltd.

      144 - BeOne Medicines Ltd. (0001651308) (Subject)

      6/6/25 4:16:22 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by BeiGene Ltd.

      EFFECT - BeOne Medicines Ltd. (0001651308) (Filer)

      6/3/25 12:15:02 AM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POSASR filed by BeiGene Ltd.

      POSASR - BeOne Medicines Ltd. (0001651308) (Filer)

      5/27/25 4:52:36 PM ET
      $ONC
      Biotechnology: Pharmaceutical Preparations
      Health Care